SGLT2 Inhibitors vs GLP-1 Agonists for Diabetes in Real-World Study
Compared with GLP-1 agonists, SGLT2 inhibitors were linked with similar cardiovascular outcomes but less heart failure, treatment discontinuation, healthcare use, and cost in a new study. Medscape Medical News
Read More